Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK39 | Q9UEW8 | 13/20 | 0.57 |
| ▸ | ACLY | P53396 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | PARG | Q86W56 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19320839 | 0.88 | ACLY (0.57) | STK39ACLYPTGS1TBXAS1MAPK1 | |
| SCHEMBL30211338 | 0.75 | STK39 (0.64) | STK39ACLYPARG | |
| SCHEMBL2167442 | 0.75 | STK39 (0.64) | STK39ACLYPARG | |
| SCHEMBL30887953 | 0.74 | STK39 (0.72) | STK39ACLYPARG | |
| SCHEMBL2168030 | 0.74 | STK39 (0.72) | STK39ACLYPARG | |
| SCHEMBL28392557 | 0.74 | HSPA5 (0.64) | STK39ACLYPTGS1TBXAS1MAPK1 | |
| SCHEMBL1715765 | 0.73 | HDAC3 (0.56) | MAPK1 | |
| SCHEMBL9868077 | 0.73 | STK39 (0.77) | STK39ACLYPTGS1TBXAS1MAPK1 | |
| SCHEMBL16138730 | 0.72 | STK39 (0.63) | STK39ACLYPTGS1TBXAS1MAPK1 | |
| Hydrochloric Acid SCHEMBL11777767 | 0.72 | STK39 (0.75) | STK39ACLYPTGS1TBXAS1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | STK39 3161/4885ACLY 2540/4885PTGS1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.